In vivo efficacy and molecular docking of designed peptide that exhibits potent antipneumococcal activity and synergises in combination with penicillin

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Le, Cheng Foh ^a,b   Yusof, Mohd Yasim Mohd ^a   Hassan, Mahmood Ameen Abdulla ^a   Lee, Vannajan Sanghiran ^a   Isa, Diyana Mohd ^a   Sekaran, Shamala Devi ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF NOTTINGHAM MALAYSIA CAMPUS   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BACTERIAL PROTEIN; N ACETYLMURAMOYLALANINE AMIDASE; PENICILLIN G; PEPTIDE; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; PNEUMOCOCCAL SURFACE PROTEIN A; PROTEIN BINDING; STREPTOLYSIN;

ANIMAL; BINDING SITE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; METABOLISM; MICROBIOLOGY; MOLECULAR DOCKING; MOLECULAR MODEL; MORTALITY; MOUSE; PATHOLOGY; PNEUMOCOCCAL INFECTIONS; PROTEIN CONFORMATION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL PROTEINS; BINDING SITES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; PENICILLIN G; PEPTIDES; PNEUMOCOCCAL INFECTIONS; PROTEIN BINDING; PROTEIN CONFORMATION; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS;

EID: 84936871662     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11886     Document Type: Article

References (33)

1. Bryce, J., Boschi-Pinto, C., Shibuya, K. & Black, R. E. WHO estimates of the causes of death in children. Lancet 365, 1147-1152 (2005).
2. Gillespie, S. H. Aspects of pneumococcal infection including bacterial virulence, host response and vaccination. J Med Microbiol 28, 237-248 (1989).
3. O'Brien, K. L. et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374, 893-902 (2009).
4. Van Der Poll, T. & Opal, S. M. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374, 1543-1556 (2009).
5. Musher, D. M. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis 14, 801-807 (1992).
6. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Report No. 0049-8114, 93-104 (2007).
7. Scott, J. A. The global epidemiology of childhood pneumonia 20 years on. Bull World Health Organ 86, 494-496 (2008).
8. Mulholland, K. Magnitude of the problem of childhood pneumonia. Lancet 354, 590-592 (1999).
9. Peltola, H. Burden of meningitis and other severe bacterial infections of children in africa: implications for prevention. Clin Infect Dis 32, 64-75 (2001).
10. Yu, V. L. et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37, 230-237 (2003).
11. Lynch, J. P., 3rd & Zhanel, G. G. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med 30, 210-238 (2009).
12. Mandell, L. A. et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2, S27-72 (2007).
13. Roson, B. et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 164, 502-508 (2004).
14. Menendez, R. & Torres, A. Treatment failure in community-acquired pneumonia. Chest 132, 1348-1355 (2007).
15. Menendez, R. et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 59, 960-965 (2004).
16. Garcia-Vidal, C. & Carratala, J. Early and late treatment failure in community-acquired pneumonia. Semin Respir Crit Care Med 30, 154-160 (2009).
17. Hancock, R. E. & Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24, 1551-1557 (2006).
18. Sang, Y. & Blecha, F. Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics. Anim Health Res Rev 9, 227-235, (2008).
19. Nizet, V. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr Issues Mol Biol 8, 11-26 (2006).
20. Kamysz, W., Okroj, M. & Lukasiak, J. Novel properties of antimicrobial peptides. Acta Biochim Pol 50, 461-469 (2003).
21. Epand, R. M. & Vogel, H. J. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1462, 11-28 (1999).
22. Hancock, R. E. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1, 156-164 (2001).
23. Wang, Y., Walter, G., Herting, E., Agerberth, B. & Johansson, J. Antibacterial activities of the cathelicidins prophenin (residues 62 to 79) and LL-37 in the presence of a lung surfactant preparation. Antimicrob Agents Chemother 48, 2097-2100 (2004).
24. Matsuzaki, K. et al. Mechanism of synergism between antimicrobial peptides magainin 2 and PGLa. Biochemistry 37, 15144-15153 (1998).
25. Turner, J., Cho, Y., Dinh, N. N., Waring, A. J. & Lehrer, R. I. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42, 2206-2214 (1998).
26. Nagaoka, I., Hirota, S., Yomogida, S., Ohwada, A. & Hirata, M. Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 49, 73-79 (2000).
27. Momany, F. A. & Rone, R. J. Validation of the general purpose QUANTA 3.2/CHARMm force field. Comp. Chem. 13, 13 (1992).
28. Kiefer, F., Arnold, K., Kunzli, M., Bordoli, L. & Schwede, T. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res 37, D387-392, (2009).
29. Schwede, T., Kopp, J., Guex, N. & Peitsch, M. C. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res 31, 3381-3385 (2003).
30. Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK: a program to check the stereo chemical quality of protein structures. J. Appl. Cryst. 26, 283-291 (2004).
31. Sippl, M. J. Boltzmann's principle, knowledge-based mean fields and protein folding. An approach to the computational determination of protein structures. Journal of computer-aided molecular design 7, 473-501 (1993).
32. Luthy, R., Bowie, J. U. & Eisenberg, D. Assessment of protein models with three-dimensional profiles. Nature 356, 83-85 (1992).
33. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry 31, 455-461 (2010).